StockData
Biohaven Ltd. logo

Biohaven Ltd. (BHVN) stock

BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$13.24−0.56 (-4.06%)

Close on Nov 17, 2026Market cap $2.00BP/E –Yield –

Biohaven ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Biohaven's ebitda for the twelve months ending Sep 30, 2026 was -$515.06M. For fiscal 2025 it was -$735.46M. The highest annual figure on record is -$114.43M in fiscal 2020.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$735.46M–
FY2024Dec 31, 2024-$877.26M–
FY2023Dec 31, 2023-$429.14M–
FY2022Dec 31, 2022-$566.55M–
FY2021Dec 31, 2021-$217.51M–
FY2020Dec 31, 2020-$114.43M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$124.20M–
Q2 FY2026Jun 30, 2026-$122.64M–
Q1 FY2026Mar 31, 2026-$128.06M–
Q4 FY2025Dec 31, 2025-$140.16M–
Q3 FY2025Sep 30, 2025-$166.26M–
Q2 FY2025Jun 30, 2025-$209.72M–
Q1 FY2025Mar 31, 2025-$219.32M–
Q4 FY2024Dec 31, 2024-$187.47M–
Q3 FY2024Sep 30, 2024-$176.17M–
Q2 FY2024Jun 30, 2024-$331.82M–
Q1 FY2024Mar 31, 2024-$181.79M–
Q4 FY2023Dec 31, 2023-$151.82M–
Q3 FY2023Sep 30, 2023-$109.01M–
Q2 FY2023Jun 30, 2023-$92.18M–
Q1 FY2023Mar 31, 2023-$76.13M–
Q4 FY2022Dec 31, 2022-$213.07M–
Q3 FY2022Sep 30, 2022-$67.26M–
Q2 FY2022Jun 30, 2022-$196.70M–
Q1 FY2022Mar 31, 2022-$89.52M–
Q4 FY2021Dec 31, 2021-$50.20M–

More Biohaven figures

See a number that looks wrong?